Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format
frozen
Storage Conditions
Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section
Preceptrol®
no
Type Strain
no
Antibiotic Resistance
Multidrug-resistance
Comments
This isolate was collected from a sputum sample of a cystic fibrosis patient during a Phase III clinical trial that tested the effectiveness of aerosolized Tobi (Tobramycin). The 1995-1996 clinical trial was conducted by a consortium led by Chiron and later acquired by Novartis AG.
Multidrug resistant
Medium
ATCC® Medium 18: Trypticase Soy Agar/Broth
Growth Conditions
Temperature: 37°C
Atmosphere: Aerobic
Name of Depositor
Chiron/Novartis
References
Ramsey BW, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328(24): 1740-1746, 1993. PubMed: 8497284
Burns JL, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27(1): 158-163, 1998. PubMed: 9675470
Burns JL, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5): 1190-1196, 1999. PubMed: 10191222
Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 120(3 Suppl): 107S-113S, 2001. PubMed: 11555564
Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 121(1): 55-63, 2002. PubMed: 11796432
